# Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats

Study · id `cardio:ct-nct06501638` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06501638](<https://clinicaltrials.gov/study/NCT06501638>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06501638

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

## Technical summary

Registry record NCT06501638. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-29 (actual); primary completion 2025-03-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT06501638, source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)
- Started: 2024-08-29 (actual) (ClinicalTrials.gov record NCT06501638, source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)
- Primary completion: 2025-03-21 (actual) (ClinicalTrials.gov record NCT06501638, source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)
- Completion: 2025-05-16 (actual) (ClinicalTrials.gov record NCT06501638, source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06501638, source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06501638-2025-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
- Acronym: STOP-AP
- Condition: Atrial Premature Beats, Contractions, or Systoles
- Intervention (Drug): Memantine Hydrochloride 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai East Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Premature heartbeats (`cardio:premature-heartbeats`)
- Registry lists this organization as the lead sponsor: Shanghai East Hospital (`cardio:org-shanghai-east-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial (`cardio:pubmed-41853846`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c60c533c43454753af75e41a59a1cefa7dcb28e49c83b7c3df2a3f3f72ba2f86
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
